Your Article Summary
See Latest ArticlesRepligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Repligen, 06/12/09
Repligen Corporation reported results for the fourth quarter and fiscal year 2009, ended March 2009. Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008 ended March 2008, an increase of $10,066,000 or 52%. Total revenue for the year was comprised of Protein A product revenue, and royalty and other revenue. Product revenue for the year was $14,529,000 and royalty and other revenue was $14,833,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia and grant revenue from the Muscular Dystrophy Association.
Today in Financial Reports...keeping you current
Receive free subspecialty "5-minute updates" via email
Bristol-Myers Squibb Sets Exchange Ratio of 0.6313 for the Exchange Offer
Bristol Myers-Squibb Company, 12/17/09
Abbott Declares 344th Consecutive Quarterly Dividend
Abbott, 12/15/09
Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09